Abstract
The practical value of the use of an agent to prolong the clotting time of the blood in the prophylaxis and treatment of thromboembolic disease has been amply demonstrated. Administration of an anticoagulant, such as heparin, has been found to be safe for operative patients immediately after 1 or even before operation. 2 Heparin has reduced the expected occurrence of thrombosis and embolism in operative patients. 1 It has served well in the management of patients with nonfatal pulmonary embolism. 1 It has materially reduced the morbidity rate associated with thrombophlebitis. 1 The principles of its use have been established. But two factors, the expense and the comparative difficulty of administration, have tempered the enthusiasm for heparin and prevented its acceptance as a measure available to all. For this reason the results of the use of another anticoagulant, dicoumarin compound, 3,3′-methylenebis-4-hydroxycoumarin, 3 have been studied in order to explore its
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
